Business Card for Barbara Yanni:


Vice President and Chief Licensing Officer
 NJ, WA area
Email Avail: 3 Day Free Trial


2000 Galloping Hill Road
Kenilworth, NJ 07033
Tel: (908) 740-4000

Last updated on 2017-11-19

About Barbara Yanni:

Barbara Yanni works as an Vice President and Chief Licensing Officer for Merck at NJ, WA. The company's webpage is http://www.merck.com. For email, phone number and executive profiles for Vice President and Chief Licensing Officer and other executives of Merck at NJ, WA, check Merck at Joesdata.com. Not the Barbara Yanni you are looking for? Do a quick search in our website and find other people named Barbara Yanni.
Barbara Yanni's Work History:
No information available..

Barbara Yanni's Education:
No information available..

Barbara Yanni's Co-workers:
As of May 28, 2022, Barbara Yanni has 2545 co-workers under the company name Merck at Joesdata.com.

About Merck:

Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company?s operations are principally managed on a products basis and consists of four segments: the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment: the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. In May 2011, it acquired Inspire Pharmaceuticals, Inc. In September 2011, the Company sold its 50% interest in the Johnson & Johnson?Merck Consumer Pharmaceuticals...... (Source: SEC reports)

Company News:
2018-09-20 19:18:49
Merck Receives Positive CHMP Opinion for DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO (doravirine) in the European Union for the Treatment of HIV-1 Infection
2018-09-20 17:30:45
Merck Receives Positive CHMP Opinion for DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO (doravirine) in the European Union for the Treatment of HIV-1 Infection
2018-09-11 19:18:41
Mercks ZERBAXA (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
2018-09-11 17:30:41
Mercks ZERBAXA (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
2018-09-10 19:18:57
European Commission Approves Mercks KEYTRUDA (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
2018-09-10 17:30:36
European Commission Approves Mercks KEYTRUDA (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
2018-09-07 17:49:50
Merck to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
2018-09-07 17:30:51
Merck to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
2018-09-06 17:30:36
Data from Mercks Leading Lung Cancer Research Program with KEYTRUDA (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer
2018-09-05 17:30:30
Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC)

People in the same industry: